ReviewCurrent oncology reports2020
The Role of Rituximab in Primary Central Nervous System Lymphoma.
Review in Current oncology reports, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
15 citing papers in PubMed, 14 citations in OpenAlex.
- Nationwide Incidence, Treatment Pattern, and Prognosis of Primary CNS Lymphoma in Taiwan, 2012-2020: A Retrospective Cohort Study.Cancer medicine · 2026Article
- Fotemustine-containing chemotherapy suggests lower toxicity with comparable efficacy versus high-dose methotrexate-based regimens: a retrospective cohort analysis.Therapeutic advances in medical oncology · 2026Article
- Neurological Infections in HIV: A Case-Based Review for Clinicians.Le infezioni in medicina · 2026Review
- The Sanctuary Within: Development of CD20+ CNS Lymphoma Despite Peripheral B-Cell Depletion by Rituximab in a Multiple Sclerosis Patient.Case reports in neurological medicine · 2026Article
- Real-world survival, cognitive, and quality of life outcomes of methotrexate/ifosfamide plus whole brain radiotherapy for newly diagnosed primary central nervous system lymphoma.Therapeutic advances in hematology · 2025Article
- A Single-Center Experience: Integrated Management in Primary Central Nervous System Lymphoma.Cureus · 2024Article
- Outcomes and relapse patterns in primary central nervous system lymphoma: Longitudinal analysis of 559 patients diagnosed from 1983 to 2020.Neuro-oncology · 2024Article
- Article
- [Primary central nervous system lymphoma in immunocompetent patient: A case report].Revista medica del Instituto Mexicano del Seguro Social · 2024Article
- Article
- Immunochemotherapy or chemotherapy alone in primary central nervous system lymphoma: a National Cancer Database analysis.Blood advances · 2023Article
- Article
- Diagnosis and management of adult central nervous system leukemia.Blood science (Baltimore, Md.) · 2023Review
- A Systematic Review of High-Dose Methotrexate for Adults with Primary Central Nervous System Lymphoma.Cancers · 2023Review
- Rituximab with high-dose methotrexate is effective and cost-effective in newly diagnosed primary central nervous system lymphoma.Scientific reports · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purpose of reviewThe treatment of primary central nervous system lymphoma (PCNSL) is still under debate. One of the issues is the role of rituximab in improving the outcome. Here, we summarize the existing evidence, and comment on the literature on this topic. RECENT
findingsTwo randomized controlled studies have been published recently, with conflicting results. Although the evidence of the benefit of rituximab is limited, it is already incorporated into many treatment regimens, both in studies and in standard clinical practice. The use of rituximab in PCNSL is still a matter of debate. A positive effect on the outcome is uncertain. However, there are no clinical signs of significantly increased toxicity. The uncertain positive effect should therefore be weighed against the increased costs of the treatment.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.